Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Outcome Measure:

Proportion of Subjects Achieving Complete Clearance of All Warts (Baseline and New) at the End of Study.

Outcome Description:

The complete clearance was defined as completely cleared all warts including baseline and newly emerged during the study at all anatomic areas.

Outcome Time Frame:

Up to 16 weeks

Safety Issue:

No

Principal Investigator

Jason Wu, MD

Investigator Role:

Study Director

Investigator Affiliation:

Graceway Pharmaceuticals

Authority:

United States: Food and Drug Administration

Study ID:

GW01-0805

NCT ID:

NCT00735462

Start Date:

August 2008

Completion Date:

July 2009

Related Keywords:

• Genital Warts
• external genital warts
• perianal warts
• condylomata acuminata
• human papilloma virus
• HPV types 6 and 11
• Condylomata Acuminata
• Warts